Marijuana as a trigger of cardiovascular events: Speculation or scientific certainty?

Aryana, Arash; Williams, Mark A.

doi:10.1016/j.ijcard.2006.08.001

Cited by 157 publications

(128 citation statements)

References 41 publications

Supporting

Mentioning

123

Contrasting

Unclassified

Order By: Relevance

“…In one case, diagnosis was asserted in view of several painful episodes which systematically occurred within an interval of 30 min after the use of cannabis. Similar cases of MI in patients with moderate tabagism and chronic use of cannabis are reported in the literature [17]. Cannabis has been shown to trigger the occurrence of angina pectoris symptoms after physical effort among patients with a history of coronary disease or stable angina pectoris, earlier than the use of tobacco [18].…”

Section: Discussionmentioning

confidence: 54%

Cannabis‐related hospitalizations: unexpected serious events identified through hospital databases

Jouanjus

Leymarie

Tubery

et al. 2011

Brit J Clinical Pharma

View full text Add to dashboard Cite

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• The general knowledge on cannabis toxicity has improved, but quantitative data are still lacking.• Little is known about the somatic complications associated with cannabis exposure. Available data rest upon case reports and only a few studies have been conducted in this field.• Psychiatric disorders related to cannabis exposure are somehow still controversial.WHAT THIS STUDY ADDS• Quantitative estimates are key to comprehending the risks of medical outcomes in cannabis users, in particular the somatic complications of use. Our study suggests that cannabis use has to be linked to serious health defects, particularly neurological and cardiovascular disorders.• Our study gives estimates of the annual incidence of cannabis‐related hospitalizations.• Our study should contribute to enhancing the medical management of cannabis using patients.AIMS Cannabis is the most prevalent illicit drug used worldwide and can be responsible for serious health defects in users. However, the risk related to cannabis consumption is not well established. The present study aimed to assess cannabis‐related adverse events leading to hospitalization, and to estimate the corresponding annual risk for consumers.METHODS Participants were patients admitted to the public hospitals in the Toulouse area (France) between January 2004 and December 2007 in relation to the use of cannabis. Reasons for admission and other occurring events were identified through hospital discharge summaries. We described all observed adverse events (AEs) and estimated their regional incidence on the basis of cannabis consumption data.RESULTS We included 200 patients, and identified a total of 619 adverse events (AEs), one of which was lethal. Psychiatric disorders involved 57.7% of patients and accounted for 18.2% of AEs. Most frequent outcomes were central and peripheral nervous system disorders (15.8% of AEs), acute intoxication (12.1%), respiratory system disorders (11.1%) and cardiovascular disorders (9.5%). We estimated that in 2007 the incidence of cannabis‐related AEs in the Midi‐Pyrenees region ranged from 1.2 per 1000 regular cannabis users (95% confidence interval (CI) 0.7, 1.6) to 3.2 (95% CI 2.5, 3.9).CONCLUSIONS Cannabis use is associated with complications, considered to be serious since they lead to hospitalization. Beyond the well‐known and widely investigated psychiatric events, serious cerebro and cardiovascular complications have been identified. These findings contribute to improve the knowledge of cannabis‐related adverse events.

show abstract

Section: Discussionmentioning

confidence: 54%

Cannabis‐related hospitalizations: unexpected serious events identified through hospital databases

Jouanjus

Leymarie

Tubery

et al. 2011

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Although his ECG findings were unremarkable, nonetheless, we made a full investigation of any cardiac pathology including echocardiography because mortality due to SCs may be related to sudden cardiac death. In the literature, cardiac side effects in the acute phase are thought to result from the stimulation of sympathetic nervous system which in turn causes release of norepinephrine (11).…”

Section: Discussionmentioning

confidence: 99%

Dangers of synthetic cannabinoids (bonzai): A case report

Karadağ¹,

Aksoy²,

Virit³

et al. 2017

Eur J Ther

View full text Add to dashboard Cite

Cannabis has become the most widely consumed illicit substance worldwide. Synthetic cannabinoids (SCs), known mostly as JWH agents, were found to have 2-100 times more potent than THC. These are obtained with very minor modifications on the original cannabinoid compound with varying chances to be detected in routine toxicological screens. Recently the use of SCs known as Bonzai has increased considerably and SC-related deaths have increased a lot. We present a male patient who was hospitalized with the history of SC (bonzai) abuse for 3 months and started to have convulsions after using SC and brought to emergency department with chest pain and loosing consciousness immediately after using SC 1 month ago. His toxicological analysis revealed no sign of illicit drugs. EEG showed paroxysmal slow waves with sharp characteristics in both hemispheres. Mortality due to SCs may be related to sudden cardiac death in the acute phase which may result from the stimulation of sympathetic nervous system and epileptic abnormalities may be due to inhibition of γ-aminobutyric acid (GABA) neurotransmission. Novel generalized seizures and chest pain especially in young people should be warning for neurologists and cardiologists in terms of potential SC abuse. Keywords: Synthetic cannabinoids, bonzai, generalized epileptic seizure ÖZKannabis dünya çapında en yaygın olarak kullanılan uyuşturucu maddedir. Daha çok JWH maddeleri olarak bilinen sentetik kannabinoidler (SK). THC maddesinden 2-100 kat daha potent etki gösterebilmektedir. SK'ler orijinal kannabinoid maddesi üzerinde yapılan çok küçük değişikliklerle elde edilmektedir ve rutin toksikolojik taramalarda bu nedenle saptanamamaktadır. Yakın zamanda bonzai olarak bilinen SK'lerin kullanımı ve buna bağlı ölüm-lerde artış gözlenmektedir. Biz üç aydır SK (bonzai) kullanan, 1 ay önce SK kullanımı sonrasında bilinç kaybı ve göğüs ağrısı şikayeti ile acil servise götürülen, SK kullanımı sonrası epileptik nöbetleri gelişen bir hastayı sunduk. Hastanın toksikolojik taramasında uyuş-turucu maddeye rastlanmamıştı. Elekroensefalografi sonucunda her iki hemisferde keskin karakterli yavaş dalgalar rapor edildi. SK kullanımına bağlı epileptik nöbetler γ-aminobütirik asit (GABA) nö-rotransmisyonunun inhibisyonuna bağlı ve mortalite artışı madde kullanımının akut döneminde gelişen sempatik sinir sistemi uyarı-mına bağlı ani kardiyak ölümler neticesinde olabilir. Genç hastalarda yeni ortaya çıkan jeneralize epileptik nöbetleri ve göğüs ağrısını değerlendirilmesinde nörologların ve kardiyologların olası SK kullanım riskini göz önünde bulundurmaları gerekmektedir.

show abstract

“…It is a common substance of abuse in the world [2]. To date, numerous cases of AMI associated with cannabis usage have been reported in the medical literature.…”

Section: Discussionmentioning

confidence: 99%

“…According to the report of the European Monitoring Centre for Drugs and Drug Addiction, 31.1% of adults in the European Union (aged 15-24 years) have tried cannabis at least once in their life [1]. Adverse effects of cannabis on the cardiovascular system have been recognized for the last four decades [2]. In the present report, we describe an adolescent with cannabisinduced recurrent left anterior descending (LAD) coronary artery thrombosis and anterior ST elevation acute myocardial infarction (AMI) even on dual anti-platelet therapy.…”

Section: Introductionmentioning

confidence: 99%

Cannabis joint triggered recurrent anterior myocardial infarction in an adolescent taking dual anti-platelet therapy

Bıyık¹,

Aktürk²,

Yalçın³

et al. 2012

pwki

View full text Add to dashboard Cite

A b s t r a c tCannabis smoking has been rising world-wide especially in industrialized western countries. It has been known that cannabis use has adverse effects on the heart and vascular system and an increased risk of acute myocardial infarction (AMI) has been reported. The actual mechanism of cannabis-related AMI is not well known. In this report, we describe an adolescent with cannabis-induced recurrent left anterior descending coronary artery thrombosis and anterior myocardial infarction even on dual anti-platelet therapy.K Ke ey y w wo or rd ds s: : cannabis, marijuana, recurrent myocardial infarction, dual anti-platelet therapy S t r e s z c z e n i ePalenie konopi indyjskich rozpowszechnia się zwłaszcza w uprzemysłowionych krajach zachodnich. Udowodniono, że negatywnie wpływa ono na serce i układ naczyniowy oraz zwiększa ryzyko wystąpienia ostrego zawału serca. Dokładny mechanizm zawału serca wywołanego przez konopie indyjskie nie jest znany. Przedstawiamy przypadek młodego pacjenta z nawrotem zakrzepicy w gałęzi przedniej zstępującej i ostrym zawałem serca, mimo stosowania podwójnej terapii przeciwpłytkowej. S Sł ło ow wa a k kl lu uc cz zo ow we e: : konopie indyjskie, marihuana, nawrót zawału serca, podwójna terapia przeciwpłytkowa

show abstract

Marijuana as a trigger of cardiovascular events: Speculation or scientific certainty?

Cited by 157 publications

References 41 publications

Cannabis‐related hospitalizations: unexpected serious events identified through hospital databases

Cannabis‐related hospitalizations: unexpected serious events identified through hospital databases

Dangers of synthetic cannabinoids (bonzai): A case report

Cannabis joint triggered recurrent anterior myocardial infarction in an adolescent taking dual anti-platelet therapy

Contact Info

Product

Resources

About